Platelet Function, Platelet Size and Content of Reticulated Platelets: Interactions in Patients Receiving Dual Antiplatelet Therapy

• Published in: Cells (Basel, Switzerland) Vol. 13; no. 20; p. 1712
• Main Authors: Bodrova, Valeria V, Shustova, Olga N, Golubeva, Nina V, Alieva, Amina K, Vlodzyanovsky, Vladislav V, Pevzner, Dmitry V, Mazurov, Alexey V
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 16-10-2024; MDPI
• Subjects: Acetylsalicylic acid; Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - pathology; Acute coronary syndromes; Aged; Aggregation; antiplatelet drugs; Antiplatelet therapy; Aspirin - pharmacology; Aspirin - therapeutic use; Blood platelets; Blood Platelets - drug effects; Blood Platelets - metabolism; Cardiac patients; Cardiology; Cardiovascular disease; Cardiovascular diseases; Clopidogrel; Clopidogrel - pharmacology; Clopidogrel - therapeutic use; Coronary artery disease; Coronary Disease - blood; Coronary Disease - drug therapy; Coronary Disease - pathology; Coronary heart disease; Diabetes; Drug development; Drugs; Dual Anti-Platelet Therapy; Epinephrine; Ethylenediaminetetraacetic acid; Female; Flow cytometry; glycoprotein IIb-IIIa; Heart diseases; Hematology; Humans; Hypertension; Male; Medical research; Medicine, Experimental; Middle Aged; P-selectin; P-Selectin - metabolism; Platelet Activation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; platelet function; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex - metabolism; platelet size; Platelets; Reagents; Research centers; reticulated platelets; Risk factors; Software; Thrombin; United States; Germany; Russia; United States > US; clopidogrel; interleukin 6; antiplatelet drugs; ticagrelor; platelet function; reticulated platelets; P-selectin; acetylsalicylic acid; glycoprotein IIb-IIIa; platelet size
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells13201712

Increased platelet activity is a risk factor of thrombotic events in cardiovascular patients. We studied the relationship between platelet function, platelet size, and the content of reticulated platelets (RP) in patients with coronary heart disease (CHD, n = 55) and acute coronary syndrome (ACS, n = 95) receiving acetylsalicylic acid + clopidogrel or ticagrelor, respectively. The control group consisted of patients with risk factors for CHD, but with no CHD/ACS and free of antiplatelet drugs (n = 66). Platelet function was evaluated by the exposure of activated glycoprotein (GP) IIb-IIIa and P-selectin. In the control group, platelets were activated by TRAP (Thrombin Receptor Activating Peptide) 10 µM, and ADP 20, 5, 2.5 µM, and in the CHD/ACS groups, by TRAP 10 µM, and ADP 20 5 µM (±epinephrine 20 µM). Platelet size was assessed by the mean volume, % large forms, and forward scattering. RP were stained by thiazole orange. In the control group, activated GP IIb-IIIa and P-selectin correlated with platelet size and RP content after platelet activation by all agonists. Despite the decrease in platelet activity by antiplatelet drugs, most correlations (primarily for activated GP IIb-IIIa) were preserved in the CHD/ACS patients. In conclusion, increased platelet size and RP content are associated with increased platelet activity and the reduced efficacy of antiplatelet therapy.